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Abstract Despite the fact that consensus guidelines rec-
ommend long-term dopamine agonist (DA) therapy as a
ﬁrst-line approach to the treatment of small prolactinoma,
some patients continue to prefer a primary surgical
approach. Concerns over potential adverse effects of long-
term medical therapy and/or the desire to become pregnant
and avoid long-term medication are often mentioned as
reasons to pursue surgical removal. In this retrospective
study, 34 consecutive patients (30 female, 4 male) prefer-
ably underwent primary pituitary surgery without prior DA
treatment for small prolactinomas (microprolactinoma
1–10 mm, macroprolactinoma 11–20 mm) at the Depart-
ment of Neurosurgery, University of Bern, Switzerland. At
the time of diagnosis, 31 of 34 patients (91%) presented
with symptoms. Patients with microprolactinomas had
signiﬁcantly lower preoperative prolactin (PRL) levels
compared to patients with macroprolactinomas (median
143 lg/l vs. 340 lg/l). Ninety percent of symptomatic
patients experienced signiﬁcant improvement of their signs
and symptoms upon surgery. The postoperative PRL levels
(median 3.45 lg/l) returned to normal in 94% of patients
with small prolactinomas. There was no mortality and no
major morbidities. One patient suffered from hypogonad-
otropic hypogonadism after surgery despite postoperative
normal PRL levels. Long-term remission was achieved in
22 of 24 patients (91%) with microprolactinomas, and in 8
of 10 patients (80%) with macroprolactinomas after a
median follow-up period of 33.5 months. Patients with
small prolactinomas can safely consider pituitary surgery
in a specialized centre with good chance of long-term
remission as an alternative to long-term DA therapy.
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Introduction
Despite the fact that consensus guidelines recommend
long-term dopamine agonist (DA) therapy as the ﬁrst-line
approach to the treatment of small prolactinomas, some
patients continue to prefer a primary surgical approach
because of concern over potential adverse effects of long-
term medical therapy and/or the desire to avoid long-
term medication [1]. Dopamine agonists (DA), especially
cabergoline, is highly efﬁcient for the treatment of small
prolactinomas [2–5]. However, following the withdrawal
of cabergoline treatment relapse of hyperprolactinemia has
been shown in a number of studies [6–10]. Furthermore,
relevant systemic side effects, including nausea, vomiting,
headache, dizziness and vertigo have been reported in
about one third of patients treated with DAs [1]. Recently,
the increased risk of cardiac valve disease in patients
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concerns about the safety of treatment with dopamine
agonists in patients with prolactinoma [11–13].
In carefully selected patients with microprolactinomas
and PRL levels less than 200 lg/l, long-term remission
rates higher than 80% can be achieved with pituitary sur-
gery [14–17]. After complete surgical resection, PRL lev-
els return to normal, gonadal function is restored in both
sexes, and the decrease in bone mineral density can be
halted and reversed. A low postoperative PRL level has
been shown to be the most reliable predictor of long term
surgical cure [14]. The surgical techniques for pituitary
surgery have been markedly improved over the last
20 years [18, 19]. Complications from pituitary surgery for
small prolactinomas are infrequent in specialized pituitary
centers [14–17]. This study was performed in order to
assess surgical outcomes in patients with small prolacti-
nomas who opted for primary pituitary surgery instead of
long-term therapy with DA.
Patients and methods
This retrospective study included 34 patients who under-
went primary pituitary surgery without prior DA treatment
for small intrasellar prolactinomas at the Department of
Neurosurgery, University of Bern, between January 2003
and December 2006. The indication for ﬁrst-line pituitary
surgery in this study was patient’s preference for surgery
rather than long-term DA therapy for all patients. A mi-
croprolactinoma was deﬁned as a tumor of 1–10 mm; a
macroprolactinoma was a lesion of 10–20 mm in diame-
ter. Preoperative data included history and physical
examination, PRL levels, and type and results of imaging
studies. Other hormonal levels were not systematically
evaluated in all patients and were hence not part of the
analysis. The highest documented preoperative value was
used as the preoperative serum level of PRL. Neurora-
diological images were reviewed to exclude extrasellar
extension and/or invasion of the cavernous sinuses [20].
All operations were performed by the single neurosurgeon
(R.W.S.), using the transseptal, transsphenoidal microsur-
gical approach while the patients were in a semi sitting
position [19, 21–23]. After a medial nasal incision, the
septal mucosa was unilaterally detached from the carti-
laginous and osseous nasal septae, respectively. A nasal
speculum was inserted to keep the mucosal tunnel open.
At this stage, the operating microscope was introduced and
the x-ray image intensiﬁer, also called ﬂuoroscopy system,
served for navigation and intra-operative imaging. Using
the operating microscope, the vomer was exposed and
opened with a drill. The septations of the sphenoid
sinus were resected. Through the sphenoid sinus, i.e.
transsphenoidally, the sellar ﬂoor was removed and the
basal dura of the pituitary fossa was incised. Variously
shaped cuvettes and micro forceps were applied to loosen
and resect the intrasellar micro- or macroprolactinoma.
The normal anterior pituitary gland was characterized by
its yellowish color, ﬁrmer consistency and vascular sur-
face structure and was preserved. After the microsurgical
removal of a micro- or macroprolactinoma, the cavity was
ﬁlled with gelatin foam soaked in ﬁbrin glue, and the
sellar opening was covered with a vicryl patch ﬁxed with
the same material. A second patch was ﬁxed to the
opening in the sella and held in place with gelatin foam
and glue. Cartilage or bone was not used for reconstruc-
tion, because the package is held in place and sealed by
ﬁbrin glue. The duration of a routine pituitary operation
was between 60 and 120 min. Antibiotic treatment was
started prophylactically before the operation and admin-
istered for 24 h. Body weight, ﬂuid intake and output,
serum electrolytes, serum and urine osmolarity were
monitored daily after surgery. Nasal tampons were
removed on the 2nd or 3rd postoperative day, and the
patients were discharged 3–5 days after the operation.
Histopathological diagnosis was based on conventional
light microscopy and speciﬁc immunohistochemistry
detecting prolactin in accordance with the WHO classiﬁ-
cation of tumours of the endocrine system [24, 25]. The
postoperative PRL level was determined on the morning
following the surgery. Remission was deﬁned as a nor-
malized PRL level below 20 lg/l on the morning after
surgery. A postoperative clinical, neuroradiological and
biochemical evaluation was performed at 6 weeks by the
operating neurosurgeon. Long-term follow-up PRL levels
which were performed at the discretion of the referring
physician and clinical symptoms of hyperprolactinemia
were obtained by the patient’s referring physician.
Recurrence was deﬁned as hyperprolactinemia ([20 lg/l)
irrespective of the presence of symptoms and neurora-
diological ﬁndings. PRL measurements were performed at
different laboratories in Switzerland. Assay kits for ELISA
or EIA differed between referral sources. At our institu-
tion, an electrochemiluminescence sandwich-immunoas-
say (Roche Modular E170, Roche Diagnostics, Mannheim,
Germany) was used. The upper limit of normal for PRL
was deﬁned as 20 lg/l. Preoperative and postoperative
PRL measurements were made with the same assay kit
during the study period. Data was entered into a com-
puterized database, after which they were analyzed using
SPSS 12.0 (SPSS, Chicago, IL, USA). If uniformly dis-
tributed, the data was subjected to Student’s t test, other-
wise a Mann–Whitney test was used. The cut-off level for
signiﬁcance was set at P\0.05. Data are presented as
medians, including the range and percentage, unless
otherwise speciﬁed.
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Clinical characteristics
Thirty four consecutive patients (30 female, 4 male)
underwent transsphenoidal microscopic removal of a small
prolactinoma at the Department of Neurosurgery (Table 1).
Mean age at surgery was 30.4 years for women, 38.5 years
for men. On the basis of magnetic resonance imaging
(MRI) ﬁndings, 24 patients (70%) had a microprolactino-
ma, and the remaining 10 (30%) had a macroprolactinoma.
At the time of diagnosis, 31 of 34 patients (91%) had
hypogonadism. Twenty eight out of 30 female patients
(93%) showed amenorrhea and/or galactorrhea. Three out
of 4 male patients (75%) complained about decreased
libido and/or impotence. Two female patients (7%) and one
male patient (25%) were asymptomatic and the adenomas
were discovered by head MRI for other medical reasons.
The median preoperative PRL concentration in the total
cohort was 203.4 lg/l (range 40–1,046 lg/l). Patients with
microprolactinomas had signiﬁcantly lower preoperative
PRL levels compared to patients with macroprolactinomas
(106.5 lg/l vs. 273 lg/l; P = 0.0004, Fig. 1). Eleven of 24
patients (45%) with microprolactinomas and 2 of 10
patients (20%) with macroprolactinomas had preoperative
PRL levels\100 lg/l.
Early postoperative results
Histologically all tumours were classiﬁed as prolactin cell
adenomas (WHO grade I) of the sparsely granulated type.
There was no evidence of invasive growth in those speci-
mens which included fragments of dura mater. The median
postoperative PRL concentration among all patients
was 3.45 lg/l (range 0.5–23.4 lg/l). This value was
Table 1 Characteristics of patients with micro- and macroprolactinomas
Characteristics Microprolactinomas 1–10 mm Macroprolactinomas 11–20 mm
n = 24 n = 10
Age (year) 30.2 (18–52) 32.6 (17–57)
Female 28.6 (18–46) 31.7 (17–57)
Male 38.5 (18–52) n/a
Sex
Female (%) 20 (83) 10 (100)
Male (%) 4 (11) n/a
Symptomatic (%) 21 (88) 8 (80)
Female (Amenorrhea and/or galactorrhea) 22 8
Male (Decreased libido and/or impotence) 3 n/a
Median time of follow-up (months, range) 30.2 (6–77) 40.3 (10–73)
Data represented as median (range) and n (%)
Fig. 1 Box plots (a and b) show preoperative and postoperative PRL
levels in the serum for patients with micro- (n = 24) and macropro-
lactinomas (n = 10). The lower and upper bars in the box plots
delineate the lowest and highest measured PRL level for both groups,
respectively. The box contains all PRL levels from the 25th to 75th
percentile. The median PRL level is shown as a line in the box. The
P-values for the preoperative (a) and postoperative PRL levels
(b) between the two groups were *P = 0.0004 and P = 0.88,
respectively
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123signiﬁcantly lower than the preoperative one of 203.4 lg/l
(range 40–1,046 lg/l). Remission, deﬁned according to
the criteria outlined in Patients and Methods was achieved
in 32 (94%) out of 34 patients. All 10 patients with
macroprolactinomas achieved remission. Patients with
microprolactinomas did not have signiﬁcantly lower post-
operative PRL levels compared to patients with macro-
prolactinomas (2.8 lg/l vs. 7 lg/l; P = 0.56, Fig. 1). No
operative or perioperative complications were recorded.
The postoperative MRI imaging after 6 weeks showed no
tumour remnants in any patients. Postoperatively, one
patient had transient SIADH which necessitated rehospi-
talization (Table 2). One patient underwent lysis of post-
operative nasal synechia. There was no mortality and no
major morbidities such as new endocrinological deﬁcits,
visual loss, vascular injury or meningitis/abscess apart
from one patient suffering from postoperative hypogo-
nadotropic hypogonadism despite postoperative normal
PRL levels.
Long-term outcome
Most patients experienced signiﬁcant improvement of their
symptoms. Twenty seven of the 30 (90%) premenopausal
women with preoperative amenorrhea resumed normal and
regular menses after surgery. Two of three premenopausal
women who did not resume normal menses had a recur-
rence of mildly elevated PRL levels (26.8 lg/l, 46.8 lg/l)
during the follow-up. One premenopausal woman is
suffering from a persistent hypogonadotropic hypogonad-
ism despite a normal prolactin level which accounts for a
new pituitary deﬁciency. In men, restoration of normal
sexual function was reported in two out of three cases
(66%). Apart from one patient with hypogonadotropic
hypogonadism, no additional patient was diagnosed with a
new pituitary deﬁciency at postoperative or long-term
evaluation. The median long-term PRL concentration in all
patients was 10.95 lg/l (range 1.6–60.1 lg/l). Patients with
microprolactinomas and those with macroprolactinomas
had similar median long-term PRL levels (10.75 lg/l vs.
10.95 lg/l, P = 0.36, Fig. 2). The median follow-up time
period was 33.5 months for all patients (range
6–77 months). Two patients (8%) with microprolactinomas
did not achieve long-term PRL levels below 20 lg/l (26.8,
38.7 lg/l). The one patient with a long-term PRL level of
26.8 lg/l had a preoperative PRL level that was above
400 lg/l. For the group of 10 patients with macroprolac-
tinomas, 2 patients (20%) had long-term PRL levels of
46.8 lg/l and 60.1 lg/l. Those two patients had preopera-
tive PRL levels above 200 lg/l, i.e. 360 and 466 lg/l,
respectively. Summarizing, three out of four patients with
recurring hyperprolactinemia had preoperative PRL levels
[200 lg/l and were medically re-evaluated. Thirty
patients with small sized prolactinomas (88%) achieved
long-term remission through surgical resection. Twenty
two of 24 patients (91%) with microprolactinomas and 8 of
10 patients (80%) with macroprolactinomas are in long-
term remission by pituitary surgery.
Discussion
The current management guidelines for prolactinomas [2]
accept pituitary surgery as a second line treatment in non-
responders to medical therapy or in those suffering intol-
erance to or complications of DA. However, some patients
continue to prefer a primary surgical approach because of
concern over potential adverse effects of long-term medical
Table 2 Neurosurgical outcomes for patients with micro- and macroprolactinomas
Neurosurgical outcomes Microprolactinomas 1–10 mm Macroprolactinomas 11–20 mm
n = 24 n = 10
PRL level (lg/l, range)
Preoperative 106.5* (40–401) 273* (48–1,046)
Postoperative 2.8 (0.5–23.4) 7 (0.5–19.5)
Long-term 10.75 (2.6–38.7) 10.95 (1.6–60.1)
Perioperative complications (%) 0 (0) 0 (0)
Morbidity
Postoperative transient (%) 1 (4); SIADH 1 (10); Nasal Synechia
Postoperative permanent (%) 1 (4); Hypogonadotropic Hypogonadism 0 (0)
Surgical Remission (PRL level\20 lg/l)
Postoperative (%) 22 (91) 10 (100)
Long-term (%) 22 (91) 8 (80)
Data represented as median (range) and n (%)
* P-value\0.05 between preoperative PRL levels in micro- and macroprolactinomas
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123therapy and/or the desire to avoid long-term medication
use. At our institution, patients can opt for surgical resec-
tion of a small prolactinoma versus long-term DA treat-
ment. Our overall remission rates of 88% for small
prolactinomas are similar to previously reported surgical
remission rates of[90 and 87.2% for microprolactinomas
[14, 15] and compare favourably with the best medical
remission rates after withdrawal of cabergoline in micro-
prolactinomas [9]. Speciﬁc selection criteria for primary
pituitary surgery have not been deﬁned. A preoperative
PRL level\200 lg/l was a strong predictor of a surgically
achieved long-term remission of hyperprolactinemia in our
study. Patients with microprolactinomas and lower preop-
erative PRL levels than patients with macroprolactinomas
(109 lg/l vs. 340 lg/l) had better remission rates (91% vs.
80%). A correlation of surgical high remission rate with
preoperative prolactin levels was previously demonstrated
in a study by Tyrell et al. 92% of the patients with pre-
operative PRL levels of\100 lg/l and 75% of the patients
with preoperative PRL levels between 101 and 200 lg/l
experienced initial remission. However, only 37% of
patients with preoperative PRL levels above [200 lg/l
achieved successful surgical outcomes [17]. It remains
unknown, why higher PRL levels appear to be a risk factor
for surgical failure for small prolactinomas [3]. Another
predictor of long term surgical cure was the postoperative
PRL level as demonstrated in a previous study of Amar
et al. [14]. Consistent with prior ﬁndings, we found that all
22 patients (100%) with microprolactinomas and 7 out of 8
patients (87%) with macroprolactinomas and postoperative
PRL levels lower than 10 lg/l achieved long-term surgical
remission. The difference in neurosurgical long-term
remission rates between micro- and macroprolactinomas
(91% vs. 80%) might suggest that complete tumour
removal is more difﬁcult to achieve with macro- than
microprolactinomas.
Complications from pituitary surgery for microadeno-
mas are uncommon. The mortality rate is typically reported
as less than 0.5%, while the rate of major morbidity has
been cited 3.4% and includes most frequently transient
diabetes insipidus, cerebrospinal ﬂuid rhinorrhea and rarely
oculomotor palsy, visual loss, stroke/vascular injury and
meningitis/abscess [26, 27]. In our cohort, one patient had
transient SIADH and another patient had to undergo lysis
of postoperative nasal synechia. One patient was diagnosed
with a new pituitary deﬁciency, in this case with hypogo-
nadotropic hypogonadism after surgery which is probably
explained by resecting a critical amount of pituitary
gonadotropic cells surrounding the small prolactinoma.
The endonasal endoscopic approach has similar compli-
cation rates compared to the traditional microsurgical
technique, but less nasal traumatism, no nasal packing, less
post-operative pain and usually quicker recovery have been
reported for endoscopic pituitary surgery [28–30]. High
surgical long-term remission rates with very low major
morbidity suggest that pituitary surgery, using the tradi-
tional operating microscope in this study, can be consid-
ered an alternative and safe option in the treatment of small
prolactinomas.
The surgical techniques for pituitary surgery have been
reﬁned over the last 20 years and have resulted in reduc-
tions in complication rates, particularly if the surgeon and
his or her institution have sufﬁcient experience in the ﬁeld
[17, 31, 32]. Many studies reporting lower surgical remis-
sion rates for prolactinomas were published more than
10 years ago. An extensive table on surgical outcomes is
provided in Gillam’s et al. [49] review. Recent surgical
studies with similar remission and complication rates to
ours were published over the last 15 years and probably
demonstrate a reﬁnement of the surgical techniques
[15–17]. Recently, no study has been published including
only patients preferably opting for primary surgical removal
of their small prolactinoma as a ﬁrst-line therapy. In the
study by Kreutzer, there were 23 patients out of 212 patients
analyzed who elected on a primary surgical approach.
However, those patients were harboring different sizes of
prolactinomas, encompassing microprolactinoma, macro-
prolactinoma and also giant prolactinomas and were not
separately discussed in the mentioned study [15]. The study
by Losa et al. also reports 21 patients (35.6%) with mi-
croprolactinomas and 14 patients (22.9%) with macropro-
lactinomas who opted for a primary surgical approach. Data
for patients with small macroprolactinoma (11–20 mm)
Fig. 2 Box-plots for long-term PRL levels in the serum for patients
with micro- (n = 24) and macroprolactinomas (n = 10) were
obtained by the patient’s referring physician after a median follow-
up period of 33.5 months. The lower and upper bars show the lowest
and highest measured long-term PRL levels for both groups,
respectively. The box contains all long-term PRL levels from the
25th to 75th percentile range. The line in the box represents the
median. The P-value for the long-term PRL levels between the two
groups was 0.11
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123have not been published separately so far. Typically, those
patients are included into the category of macroprolacti-
nomas which have a much lower reported initial remission
rate of 35% compared to our initial remission rate of 100%
in patients with macroprolactinomas [3]. To further deter-
mine the optimal management of small prolactinomas, a
large number of patients with a longer follow up, prefer-
entially in the setting of a randomized study, need to be
studied.
The recurrence rate of 8.9% in this study for patients
with microprolactinomas is comparable with the recurrence
rate of 5.6% for microprolactinoma reported in the study
by Kreutzer et al. [15]. Losa et al. reported a recurrence
rate of 16.9% in their study which was similar to most
other recent surgical series [17, 32–34]. Given the median
follow-up period of 33.5 months in this study, the possi-
bility of a later recurrence of hyperprolactinemia needs to
be reassessed. As shown in Fig. 3, Panel A and B the long-
term PRL levels in selected patients might rise over 20 ng/ll
over a longer follow-up period. The relapse of hyperpro-
lactinema varied widely among different surgical series. In
some studies almost all relapses occurred within the ﬁrst
3 years after surgery [35–37], whereas in other studies the
median time to relapse was longer than 5 years [17, 38].
The median follow-up period of 33.5 months (range
6–77 months) in this study is therefore an important limi-
tation, especially for patients in the shorter range of the
follow-up period. The relapse of hyperprolactinemia might
indicate microscopic remnants after pituitary surgery
which might grow back to a tumor entity over an extended
period of time. Those microscopic remnants might not be
detected by postoperative MRI imaging and regular PRL
levels assays over a longer-follow up period, because most
small prolactinomas have very low proliferative cell
indexes [39]. The study by Delgrange et al. reports only
occasional Ki-67- or PCNA-positive nuclei (\1%) in a
series of 14 female microprolactinomas. In the cohort of
Thomson’s et al. [38] who reported 44 patients with con-
ﬁrmed microprolactinoma, 8 patients (18.2%) experienced
recurrent hyperprolactinemia at 2–10 years, but the eleva-
tion was permanent in only two patients. Thomson et al.
concluded that the recurrence of hyperprolactinemia after
pituitary surgery for microprolactinomas is not necessarily
a permanent feature and does not inevitably indicate
operative failure. However, we would suggest DA treat-
ment for patients with recurrent hyperprolactinemia after a
primary surgical approach if the hyperprolactinemia per-
sists over 2 months.
Dopamine agonists have been efﬁcient overall in the
treatment of hyperprolactinemia. Cabergoline, the most
effective compound, is a D2 selective agonist and induces
fewer side effects than bromocriptine [40, 41]. In a high
percentage of patients, PRL normalization and tumor
reduction have been shown upon treatment with cabergo-
line in several prospective studies [7–9, 42]. For cabergo-
line, the most common side effects are nausea or vomiting
(*35%), followed by headache (*30%) and dizziness or
vertigo (*25%) [1]. After withdrawal of cabergoline, 30%
of carefully selected patients had recurrent hyperprolacti-
nemia in a study reported by Colao et al. [9]. Patients
needed to meet following criteria for discontinuation of
cabergoline: normal serum prolactin levels, no visible
tumor on MRI scan, or a 50% decrease or more from
baseline with a tumor mass at least 5 mm from the optic
chiasm and no evidence of cavernous sinus invasion. In the
study by Kharlip et al. [10] more than half of the patients
(54%) meeting similar discontinuation criteria experienced
recurrence of hyperprolactinemia within a year. In both
studies, there was a strong correlation between the size of
the tumor remnant and recurrence of hyperprolactinemia.
In several other studies on unselected patients, even higher
recurrence rates of hyperprolactinemia have been reported
[6–8].
Although the side effects of dopamine agonist therapy
such as nausea, headache, and dizziness are well known,
Fig. 3 Postoperative and long-term PRL levels in the serum for
individual patients with small prolactinomas. a Twenty four individ-
ual postoperative and long-term PRL levels for patients with
microprolactinomas. The values are shown by a black dots connected
by a line. b Postoperative and long-term PRL values connected by a
line for all 10 individual patients with microprolactinomas
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recently arisen in patients with long-term DA treatment.
Increased risk of valvular heart disease was ﬁrst reported in
patients with Parkinson’s disease (PD) who were treated
with very high doses of cabergoline or pergolide, showing
a cumulative dose and duration effect [11, 12]. Cabergoline
or pergolide are potent serotonin 2B receptor (5-HT2B)
agonists and stimulate 5-HT2B receptors on normally qui-
escent valvular cells [43, 44]. The stimulation of 5-HT2B
receptors, which is known to activate several mitogenic
pathways, appears to be a key step in initiating cabergo-
line-or pergolide induced valvular heart disease in patients
with PD [44]. In several studies on the association between
PD and valvular heart disease, the cumulative dose ranged
between 2,600 and 6,700 mg, whereas it ranged between
200 and 443 mg in similar studies on hyperprolactinemic
patients [45]. Seven of eight observational studies on the
effects of cabergoline in hyperprolactinemic patients do not
show an association between cabergoline therapy and
clinically relevant, i.e. moderate or severe valvular disease,
whereas one study found an increased rate of moderate
tricuspid regurgitation [46–51]. Within these eight obser-
vational studies, two showed an increased prevalence of
mild tricuspid regurgitation [52, 53]. A recent meta-anal-
ysis by Bogazzi et al. [49] which pooled data from six
clinical studies on hyperprolactinemic patients treated with
cabergoline showed an increased risk of regurgitation of
the tricuspid valve. One study also found increased thick-
ening and calciﬁcations of cardiac valves in patients treated
with cabergoline compared with controls [51]. Though
onset of cardiac valve disease is not associated with ca-
bergoline treatment in patients with prolactinoma, subtle
changes in cardiac valves such as calciﬁcations, thickening
and increased mitral tenting area have been observed in a
subset of studies [50–52] and might predispose to more
severe and clinically relevant changes in patients to whom
cabergoline treatment is given long-term or in high doses.
The management of small prolactinomas in pregnant
women can be complex [54, 55]. In our series no patient
was pregnant, but some of the patients who opted for a
primary surgical approach in this study wished to become
pregnant and avoid long-term DA medication. Only a small
percentage (2.2–4.5%) of pregnant women with micro-
prolactinomas experience a symptomatic tumor enlarge-
ment (headaches and/or visual disturbances) during
gestation [56]. However, 40% of pregnant women with
microprolactinomas demonstrate asymptomatic tumour
growth [57]. During pregnancy, rising estrogen levels
stimulates PRL synthesis and promotes lactotrope cell
hyperplysia [58]. Most patients will require treatment of
hyperprolactinemia to restore fertility. With a primary
surgical approach, DA therapy can be avoided in a patient
to restore ovulation. Therefore, the foetus is not exposed to
either bromocriptine or cabergoline for at least three to
4 weeks of gestation, until a pregnancy test can verify
conception and the DA medication can be discontinued.
DAs are not approved for use during pregnancy. Caberg-
oline and bromocriptine treatment at the time of conception
appears to be safe for both the pregnant patient and the
neonate, showing rates of spontaneous abortions (11%) and
neonatal malformations (3.5%) similar to those rates in
normal population [57, 59–61]. However, reinstitution of
the DA or surgical debunking/removal is indicated if
symptomatic enlargement of a prolactinoma occurs.
Conclusion
Prolactinomas are the most common neoplasm of the
anterior pituitary gland. Treatment of hyperprolactinemia
is indicated because of resulting infertility, gonadal dys-
function and osteoporosis. The data presented here shows
high long-term remission rates for primarily surgically
treated small prolactinomas (88%) with very low major
morbidity rates in a specialized pituitary centre. Patients
with small prolactinomas can therefore consider pituitary
surgery as an alternative to treatment with DA. The like-
lihood of achieving long-term remission is high, especially
if preoperative PRL levels are below 200 lg/l. However,
the possible recurrence of hyperprolactinemia after pitui-
tary surgery needs to be addressed. Long-term DA medi-
cation and potential long-term side effects can be avoided
in carefully selected patients opting for primary pituitary
surgery.
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